FindTrial
Sign In

Effect of Iron Chelation Therapy on Glucose Metabolism in Non-Transfusion-Dependent Thalassemics

Effect of Iron Chelation Therapy on Glucose Metabolism in Non-Transfusion-Dependent Thalassemics

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
TCTR
Registry ID
TCTR20160523003
Enrollment
Unknown
Registered
2016-05-23
Start date
2015-05-18
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subject with non&#45

Interventions

Subjects with NTDT&#44
aged older than 10 years having serum ferritin >300 ng/mL were included. Iron chelation therapy with deferasirox (10 mg/kg/d) had been commenced for 6 months.
No Intervention Drug
Deferasirox

Sponsors

No
Lead Sponsor

Eligibility

Sex/Gender
All
Age
10 Years to 20 Years

Inclusion criteria

Inclusion criteria: Patients with NTDT, aged older than 10 years, with serum ferritin >300 ng/mL. All patients and/or parents provided written consent before the enrollment.

Exclusion criteria

Exclusion criteria: Known cases of type 1 or type 2 diabetes mellitus and patients, taking medications affecting glucose metabolism or iron chelation therapy within one month before the study, were excluded.

Design outcomes

Primary

MeasureTime frame
Iron status At 6 months Serum ferritin, MRI study—

Secondary

MeasureTime frame
No No No—

Countries

Thailand

Contacts

Public ContactAmpaiwan Chuansumrit

Faculty of Medicine Ramathibodi Hospital, Mahidol University

ampaiwan.jua@mahidol.ac.th0818338494

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026